Ustekinumab

Drug Profile

Ustekinumab

Alternative Names: Anti-IL-12/23p40 monoclonal antibody; Anti-interleukin-12 p40 monoclonal antibody; CNTO-1275; STELARA; Stelara

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriatic arthritis
  • Registered Crohn's disease
  • Phase III Spondylarthritis; Ulcerative colitis
  • Phase II Atopic dermatitis; Systemic lupus erythematosus
  • Phase I Inflammation
  • Discontinued Multiple sclerosis; Palmoplantar pustulosis; Primary biliary cirrhosis; Rheumatoid arthritis; Sarcoidosis

Most Recent Events

  • 17 Feb 2017 Efficacy and adverse events data from the phase III IM-UNITI long-term extension trial in Crohn’s disease released by Janssen-Cilag
  • 03 Feb 2017 Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K. agree to co-promote ustekinumab in Japan for Crohn's disease
  • 03 Feb 2017 Preregistration for Crohn's disease in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top